MX2022012192A - Composiciones de vacuna para el tratamiento de coronavirus. - Google Patents
Composiciones de vacuna para el tratamiento de coronavirus.Info
- Publication number
- MX2022012192A MX2022012192A MX2022012192A MX2022012192A MX2022012192A MX 2022012192 A MX2022012192 A MX 2022012192A MX 2022012192 A MX2022012192 A MX 2022012192A MX 2022012192 A MX2022012192 A MX 2022012192A MX 2022012192 A MX2022012192 A MX 2022012192A
- Authority
- MX
- Mexico
- Prior art keywords
- coronavirus
- treatment
- compositions
- vaccine compositions
- methods
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 241000711573 Coronaviridae Species 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title 1
- 241000713869 Moloney murine leukemia virus Species 0.000 abstract 2
- 101710132601 Capsid protein Proteins 0.000 abstract 1
- 208000001528 Coronaviridae Infections Diseases 0.000 abstract 1
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063002237P | 2020-03-30 | 2020-03-30 | |
| US202063070150P | 2020-08-25 | 2020-08-25 | |
| PCT/IB2021/000190 WO2021198769A1 (en) | 2020-03-30 | 2021-03-30 | Vaccine compositions for the treatment of coronavirus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022012192A true MX2022012192A (es) | 2022-10-27 |
Family
ID=77927072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022012192A MX2022012192A (es) | 2020-03-30 | 2021-03-30 | Composiciones de vacuna para el tratamiento de coronavirus. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11253587B2 (https=) |
| EP (1) | EP4126038A4 (https=) |
| JP (1) | JP2023519837A (https=) |
| KR (1) | KR20230008707A (https=) |
| AU (1) | AU2021247583A1 (https=) |
| BR (1) | BR112022019672A2 (https=) |
| CA (1) | CA3142132C (https=) |
| IL (1) | IL296578A (https=) |
| MX (1) | MX2022012192A (https=) |
| WO (1) | WO2021198769A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12558415B2 (en) * | 2020-04-14 | 2026-02-24 | The Regents Of The University Of California | Broad-spectrum multi-antigen pan-coronavirus vaccine |
| WO2021234579A1 (en) * | 2020-05-19 | 2021-11-25 | National Research Council Of Canada | Use of resistin as a trimerization partner for expression of trimeric proteins |
| WO2022051859A1 (en) * | 2020-09-11 | 2022-03-17 | Manuel Caruso | Pseudotyped retroviral particles for inducing immunity against coronavirus infections |
| KR102744743B1 (ko) * | 2021-10-25 | 2024-12-19 | 경희대학교 산학협력단 | SARS-CoV-2의 스파이크 단백질 전부 또는 일부를 포함하는 바이러스 유사입자 및 이를 이용한 백신 |
| EP4719470A1 (en) * | 2023-06-02 | 2026-04-08 | Variation Biotechnologies Inc. | Compositions of mrna-encoded virus-like particles, compositions of mrna-lipid nanoparticles, and methods for use thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5500161A (en) | 1993-09-21 | 1996-03-19 | Massachusetts Institute Of Technology And Virus Research Institute | Method for making hydrophobic polymeric microparticles |
| WO2005118813A2 (en) * | 2004-06-04 | 2005-12-15 | Institut Pasteur | Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein |
| JP6046348B2 (ja) | 2008-11-18 | 2016-12-14 | タケダ ヴァクシーンズ， インコーポレイテッド | Ｒｓｖｆｖｌｐならびにその製造および使用の方法 |
| US8920812B2 (en) | 2009-11-03 | 2014-12-30 | Takeda Vaccines, Inc. | Chimeric RSV-F polypeptide and lentivirus or alpha-retrovirus Gag-based VLPS |
| WO2011115583A1 (en) | 2010-03-19 | 2011-09-22 | National University Of Singapore | A novel platform for retrovirus-like particle (vlp)-display of vaccine antigens |
| WO2014128568A2 (en) * | 2013-02-25 | 2014-08-28 | Variation Biotechnologies, Inc. | Compositions and methods for treatment of hepatitis c |
| MX2019000725A (es) * | 2016-07-18 | 2019-07-04 | Variation Biotechnologies Inc | Composiciones de vacuna para tratamiento de virus zika. |
-
2021
- 2021-03-30 KR KR1020227037855A patent/KR20230008707A/ko active Pending
- 2021-03-30 JP JP2022557696A patent/JP2023519837A/ja active Pending
- 2021-03-30 WO PCT/IB2021/000190 patent/WO2021198769A1/en not_active Ceased
- 2021-03-30 CA CA3142132A patent/CA3142132C/en active Active
- 2021-03-30 MX MX2022012192A patent/MX2022012192A/es unknown
- 2021-03-30 AU AU2021247583A patent/AU2021247583A1/en not_active Abandoned
- 2021-03-30 US US17/218,148 patent/US11253587B2/en not_active Expired - Fee Related
- 2021-03-30 EP EP21782275.8A patent/EP4126038A4/en not_active Withdrawn
- 2021-03-30 IL IL296578A patent/IL296578A/en unknown
- 2021-03-30 BR BR112022019672A patent/BR112022019672A2/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3142132C (en) | 2024-06-04 |
| IL296578A (en) | 2022-11-01 |
| AU2021247583A1 (en) | 2022-11-03 |
| KR20230008707A (ko) | 2023-01-16 |
| WO2021198769A8 (en) | 2021-12-23 |
| CA3142132A1 (en) | 2021-10-07 |
| WO2021198769A9 (en) | 2022-03-03 |
| EP4126038A4 (en) | 2024-04-17 |
| JP2023519837A (ja) | 2023-05-15 |
| EP4126038A1 (en) | 2023-02-08 |
| US20210353741A1 (en) | 2021-11-18 |
| WO2021198769A1 (en) | 2021-10-07 |
| US11253587B2 (en) | 2022-02-22 |
| BR112022019672A2 (pt) | 2023-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022012192A (es) | Composiciones de vacuna para el tratamiento de coronavirus. | |
| MX2019000725A (es) | Composiciones de vacuna para tratamiento de virus zika. | |
| WO2021243122A3 (en) | Engineered coronavirus spike (s) protein and methods of use thereof | |
| ZA202300260B (en) | Stabilized coronavirus spike (s) protein immunogens and related vaccines | |
| WO2022221335A8 (en) | Respiratory virus combination vaccines | |
| WO2022221440A8 (en) | Influenza-coronavirus combination vaccines | |
| MX2021005607A (es) | Proteinas f de prefusion del vrs estabilizadas. | |
| MX353189B (es) | Composiciones y su uso en el tratamiento de citomegalovirus. | |
| WO2009152147A3 (en) | Compositions and methods for dengue virus (dv) treatment and vaccination | |
| CA2817005A1 (en) | Rabies glycoprotein virus-like particles (vlps) | |
| WO2017214596A8 (en) | Compositions and methods for preventing and treating zika virus infection | |
| EA201990010A1 (ru) | Вакцина против вируса инфекционного бронхита | |
| MY207126A (en) | 4/91 ibv vaccine with heterologous spike protein | |
| WO2023064612A3 (en) | Pharmaceutical compositions for delivery of viral antigens and related methods | |
| PH12021550441A1 (en) | Modified pedv spike protein | |
| WO2014128568A3 (en) | Compositions and methods for treatment of hepatitis c | |
| MX2022014598A (es) | Anticuerpos anti-glicoproteína espicular sars-cov-2 y fragmentos de unión al antígeno. | |
| MX2024014492A (es) | Composiciones de arn para la administracion de antigenos de viruela simica y metodos relacionados | |
| MX2020009851A (es) | Anticuerpos anti-pfrh5 y fragmentos de unión al antígeno de estos. | |
| WO2022173714A3 (en) | Antibodies that bind metapneumovirus, antigenic metapneumovirus proteins, and uses thereof | |
| MX2022015489A (es) | Vacuna de virus vaccinia modificado de ankara (mva) recombinante contra la enfermedad del coronavirus. | |
| MX2023014984A (es) | Anticuerpos anti-csp. | |
| EA201890187A1 (ru) | Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита | |
| WO2021158755A3 (en) | Leptospiral proteins and uses thereof | |
| ZA202309368B (en) | Lentiviral vector, lentiviral particle for treating hepatitis b and its preparation method and application thereof |